ewsba.se
CG Oncology, Inc. (NASDAQ:CGON) is one of the best performing healthcare stocks so far in 2026. RBC Capital lifted the price target on CG Oncology, Inc. (NASDAQ:CGON) to $79 from $73 on April 27, reaffirming an Outperform rating on the shares. The firm told investors in a research note that one of the most complex catalysts in the firm’s universe is PIVOT-006, given the recent run-up and future catalyst path from a tactical perspective, as well as the limited data from which to base readout expectations on a fundamental basis. The firm added that it anticipates data from the trial in early June and expects to deliver a 40% risk reduction, driving 20% upside in shares.
CG Oncology, Inc. (NASDAQ:CGON) also received a rating update from BofA on April 14. The firm lifted the price target on the stock to $84 from $72, maintaining a Buy rating on the shares. It stated that shares have run up 62% year-to-date with the acceleration of the timeline for PIVOT-006 IR NMIBC data, adding that the BofA is “still bullish at current levels” and sees “more room to run.”
CG Oncology, Inc. (NASDAQ:CGON) is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutic patients afflicted with bladder cancer. The company offers cretostimogene, which is a product initially in clinical development to treat patients with Non-Muscle Invasive Bladder Cancer (NMIBC).
While we acknowledge the potential of CGON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.